Cargando…

Development and implementation of an electronic Clinical Dementia Rating and Financial Capacity Instrument‐Short Form

INTRODUCTION: To address the need for remote assessments of cognitive decline and dementia, we developed and administered electronic versions of the Clinical Dementia Rating (CDR®) and the Financial Capacity Instrument‐Short Form (FCI‐SF) (F‐CAP(®)), called the eCDR and eFCI, respectively. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Howell, Taylor, Gummadi, Shilpa, Bui, Chau, Santhakumar, Jessica, Knight, Kristen, Roberson, Erik D., Marson, Daniel, Chambless, Carol, Gersteneker, Adam, Martin, Roy, Kennedy, Richard, Zhang, Yue, Morris, John C., Moulder, Krista L., Mayo, Connie, Carroll, Maria, Li, Yan, Petersen, Ronald C., Stricker, Nikki H., Nosheny, Rachel L., Mackin, Scott, Weiner, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309008/
https://www.ncbi.nlm.nih.gov/pubmed/35898521
http://dx.doi.org/10.1002/dad2.12331
Descripción
Sumario:INTRODUCTION: To address the need for remote assessments of cognitive decline and dementia, we developed and administered electronic versions of the Clinical Dementia Rating (CDR®) and the Financial Capacity Instrument‐Short Form (FCI‐SF) (F‐CAP(®)), called the eCDR and eFCI, respectively. METHODS: The CDR and FCI‐SF were adapted for remote, unsupervised, online use based on item response analysis of the standard instruments. Participants completed the eCDR and eFCI first in clinic, and then at home within 2 weeks. RESULTS: Of the 243 enrolled participants, 179 (73%) cognitively unimpaired (CU), 50 (21%) with mild cognitive impairment (MCI) or dementia, and 14 (6%) with an unknown diagnosis, 84% and 85% of them successfully completed the eCDR and eFCI, respectively, at home. DISCUSSION: These results show initial feasibility in developing and administering online instruments to remotely assess and monitor cognitive decline along the CU to MCI/very mild dementia continuum. Validation is an important next step.